公开(公告)号：US20220323558A1

公开(公告)日：2022-10-13

申请号：US17319395

申请日：2021-05-13

Applicant: Pfizer Inc.

Inventor： Joseph John Binder ,  Paul Jason Cockle ,  Derek John Falconer ,  Siradanahalli Guru ,  Karin Ute Jooss ,  Marianne Marcela Andrea Martinic ,  Kenneth Nelson Wills ,  Helen Kim Cho

IPC: A61K39/00 ,  A61K48/00

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.

公开(公告)号：US20190142918A1

公开(公告)日：2019-05-16

申请号：US16252239

申请日：2019-01-18

Applicant: Pfizer Inc.

Inventor： Joseph John Binder ,  Paul Jason Cockle ,  Derek John Falconer ,  Siradanahalli Guru ,  Karin Ute Jooss ,  Marianne Marcela Andrea Martinic ,  Kenneth Nelson Wills ,  Helen Kim Cho

IPC: A61K39/00 ,  A61K48/00

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.

公开(公告)号：US10251944B2

公开(公告)日：2019-04-09

申请号：US15407890

申请日：2017-01-17

Applicant: Pfizer Inc.

Inventor： Joseph John Binder ,  Paul Jason Cockle ,  Derek John Falconer ,  Siradanahalli Guru ,  Karin Ute Jooss ,  Marianne Marcela Andrea Martinic ,  Kenneth Nelson Wills ,  Helen Kim Cho

IPC: A61K39/00 ,  A61K31/711 ,  C12N15/12 ,  C12N15/62 ,  A61K48/00

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.

公开(公告)号：US11058753B2

公开(公告)日：2021-07-13

申请号：US16252239

申请日：2019-01-18

Applicant: Pfizer Inc.

Inventor： Joseph John Binder ,  Paul Jason Cockle ,  Derek John Falconer ,  Siradanahalli Guru ,  Karin Ute Jooss ,  Marianne Marcela Andrea Martinic ,  Kenneth Nelson Wills ,  Helen Kim Cho

IPC: A61K39/00 ,  C12N15/62 ,  A61K48/00 ,  A61K31/711

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.

公开(公告)号：US20170202938A1

公开(公告)日：2017-07-20

申请号：US15407890

申请日：2017-01-17

Applicant: Pfizer Inc.

Inventor： Joseph John Binder ,  Paul Jason Cockle ,  Derek John Falconer ,  Siradanahalli Guru ,  Karin Ute Jooss ,  Marianne Marcela Andrea Martinic ,  Kenneth Nelson Wills ,  Helen Kim Cho

IPC: A61K39/00

CPC classification number: A61K39/0011 ,  A61K2039/53 ,  A61K2039/57 ,  A61K2039/575 ,  A61K2039/585 ,  A61K2039/70

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.